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There is no evidence for an association between 3 SNPs in 
the  IL10  gene promoter and susceptibility to PKDL in the Ma-
salit ethnic group in Sudan, although some evidence for 
haplotype association was observed. 
  Copyright © 2009 S. Karger AG, Basel 
  In Sudan post kala-azar dermal leishmaniasis (PKDL) 
is a known complication of visceral leishmaniasis (VL) 
caused by   Leishmania donovani   and occurs in some pa-
tients after treatment and cure of VL. PKDL occurs with 
a frequency of 56–62%, usually after a latent phase from 
months to years  [1, 2] . Clinical characterization of the dis-
ease was previously described   [3]  . Experimental studies 
indicate that interleukin 10 (IL-10) plays an important 
regulatory role in the progression of VL. IL-10 was the 
most prominent cytokine in PKDL lesions   [4]   with high 
levels also observed in plasma   [5]  . However, interferon-    
(IFN-    ) was also seen in all lesions   [4]   and was detected 
in keratinocytes and/or sweat glands of patients who de-
veloped PKDL. In response to leishmanial antigens, pe-
ripheral blood mononuclear cells from most Sudanese 
PKDL patients proliferate and produce IFN-     and IL-10 
  [4, 5] . Silva et al. (1992) postulated that the presence of IL-
10 in the skin lesions could block the action of IFN-   , 
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 Abstract 
  Background:  Post kala-azar dermal leishmaniasis (PKDL) is a 
cutaneous form of disease that develops at variable times 
after individuals have received treatment for clinical visceral 
leishmaniasis (VL). The study aimed to investigate the pos-
sible role of interleukin 10 (IL-10) and development of PKDL. 
  Methods:   77 families composed of 41 complete case-par-
ent trios and 36 case-parent pairs from the Masalit ethnic 
group were genotyped for 3   IL10   promoter polymorphisms: 
-1082A/G, -819C/T and -592C/A.   Results:   Single point analy-
sis using the transmission disequilibrium test showed no ev-
idence of association between any of these   IL10   promoter 
single nucleotide polymorphisms (SNPs) and development 
of PKDL. Haplotype analysis performed using TRANSMIT 
showed borderline significance between PKDL and the hap-
lotype AA across -592C/A and -1082A/G (p = 0.053). Haplo-
types GCC (0.33) and ATA (0.30) were the common haplo-
types in this Sudanese population. Allele frequencies for the 
3 SNPs differed significantly in Sudan compared to other Af-
rican (Gambian, Malawian, YRI) populations.   Conclusion:  
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rather than inhibit its production   [6]  . In mice, IL-10 was 
found to play an important role in parasite persistence as 
sterile cure was detected in IL-10 deficient mice on a re-
sistant genetic background   [7]  . Recently IL-10 was found 
to be strongly associated with development of ulcerated 
skin lesions in   L. braziliensis   infection in humans, sup-
ported by data showing genetic associations for single nu-
cleotide polymorphisms (SNPs) across the   IL10  gene  and 
evidence that the -819C/T SNP in the  IL10  promoter plays 
a functional role in determining binding of nuclear tran-
scription factors and levels of   IL10   gene expression   [8] .
  In the present study we investigated the  IL10  promoter 
polymorphisms -1082A/G, -819C/T, and -592C/A. The 
importance of   IL10   three selected polymorphisms has 
been documented in several disease processes by inde-
pendent studies. The -592C/A SNP lies within negative 
regulatory elements in the promoter  [9] . It has been shown 
that the -592C/A polymorphism is associated with di-
minished IL10 production   [10]  . Different studies report-
ed the functional role of -1082A/G polymorphisms. Turn-
er et al. found that lymphocytes with the GG genotype 
responded with significantly enhanced IL-10 secretion 
compared to those with the AA genotype   [11] .  Another 
study showed high IL-10 plasma levels was associated 
with the -1082A allele in the Dutch population   [12] .  The 
-1082A allele was able to confer an increase in transcrip-
tional activity of the   IL-10   promoter   [13]  . The study pre-
sented here looked for association between these SNPs 
and the development of PKDL.
  Material  and  Methods 
 Ethical approval for this study was obtained from the Institute 
of Endemic Diseases, University of Khartoum Ethical Commit-
tee. The study was conducted in the region of the Rahad River in 
Eastern Sudan where VL and PKDL are endemic. Samples were 
collected from individuals belonging to the Masalit tribe who are 
highly susceptible to VL and PKDL   [14–16]  . Trios with PKDL 
were ascertained from epidemiological and medical records of the 
Institute of Endemic Diseases. Diagnosis was made on the basis 
of clinical, parasitological and serological criteria as described 
previously   [14, 17]  . Epidemiological and demographic details re-
lating to the study site are also described in detail elsewhere   [14] . 
DNA was extracted from buccal swap samples and successfully 
genotyped for 77 families that composed of 41 complete case-
parent trios and 36 case-parent pairs (i.e. one parent missing). 
Amplification refractory mutation system (ARMS-PCR) was
employed to genotype the -1082A/G (rs1800896) and -819C/T 
(rs1800871) using primers previously described   [18]   with specific 
sequence for both alleles, wild and mutant type and common 
primer. The -1082A/G primers were: common 5   -cagtgccaact-
gagaatttgg-3    ; mutant type 5   -ctactaaggcttctttggga  g  -3   ; and wild 
type 5   -actactaaggcttctttggga  a  -3    The -819C/T primers were: 
common 5   -aggatgtgttccaggctcct-3   ; mutant type 5   -acccttgta-
caggtgatgtaa   t  -3   ; and wild type 5   -cccttgtacaggtgatgtaa  c  -3  . 
  Human growth factor hormone primers were included in each 
PCR reaction as internal control: forward primer 5   -gccttcccaac-
cattccctta-3    and reverse primer 5  -tcacggatttctgttgttttc-3  . ARMS 
PCR to detect the 2 polymorphisms (-819C/T) and (-1082A/G) 
was carried out in a total volume of 10.5     l composed of; 1  !  Bio-
line PCR reaction buffer, 2 m  M   MgCl 2  , 10 m  M  dNTPs, 1 unit Taq 
polymerase, 10     M  of each oligonucleotide, 0.5     M  of internal 
control primers and 5     l of dd H  2 O.
    A touch down program was used as follows: denaturation at 
96°C for 1 min, 9 cycles contain denaturation at 96°C for 35 s, an-
nealing at 63°C for 45 s and elongation at 72°C for 35 s, 27 cycles 
of denaturation at 96°C for 25 s, annealing at 59°C for 50 s and 
elongation at 72°C for 40 s. Finally 9 cycles comprising denatur-
ation at 72°C for 5 min, annealing at 55°C for 1 min and elonga-
tion at 72°C for 90 s were carried out. The PCR product was run 
in 2% agarose gel stained with ethidium bromide, visualized and 
photographed by gel documentation system. Genotype scoring 
was based on the presence or absence of target bands.
    A restriction fragment length polymorphism (PCR-RFLP) 
was used to genotype the -592C/A (rs1800872) SNP, using for-
ward primer 5   -ataaaatagagacggtaggg-3    and reverse primer    5  -
ggctaaatatcctcaaagtt-3    . The PCR reaction was carried out in a 
total volume 21.2   l composed of 1 !  Bioline PCR reaction buffer, 
2 m M  MgCl 2 , 10 m M  dNTPs, 1 unit Taq polymerase, 10    M  of each 
primers and 8.3     l of dd H  2  O. The PCR conditions were: dena-
turation at 95°C for 5 min, 35 cycles of denaturation at 95°C for 
30 s, annealing at 57°C for 30 s, elongation at 72°C for 45 s and 
final extension at 72°C for 10 min. The PCR product was digested 
by   Rsa I   restriction  enzyme    as for 3 h at 37°C. The digested prod-
ucts were run in 2.5% agarose gel, stained with bromide, visual-
ized and photographed by gel documentation system.
  Deviation from Hardy-Weinberg Equilibrium (HWE) was de-
termined using a set of unrelated individuals from the families 
(parents), excluding any with PKDL. Tests for HWE were per-
formed within STATA 9.1 (http://www.stata.com/) using the
GenAssoc package (http://www-gene.cimr.cam.ac.uk/clayton/
software/stata/). Tests for linkage disequilibrium (LD) between 
SNPs were performed using Haploview v3.32 (www.broad.mit.
edu/mpg/haploview/). Single point and haplotype association 
tests (haplotype-based score tests) were performed using the 
transmission disequilibrium test (TDT) in the program TRANS-
MIT (http://www-gene.cimr.cam.ac.uk/clayton/software/) which 
takes account of missing parental genotype data. Genotype and 
allele frequencies in our study population were compared with 
other African groups, Mandinka, Wolf and Jola groups from 
Gambia   [19]  , Bantu from Karonga district in Malawian   [20] ,  and 
the YRI HapMap data.
  R e s u l t s  
  Representative genotyping data for all 3 SNPs are 
shown in   figures 1–3  . For the -592C/A SNP, a PCR prod-
uct of 269 bp is obtained (  fig. 1  ). Digestion with   Rsa I  re-
striction enzyme results in 2 bands for the mutant allele  Farouk   /Salih   /Musa   /Blackwell   /Miller   /
Khalil    /ElHassan   /Ibrahim   /Mohamed   
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equivalent to 201 bp and 68 bp, while the normal allele 
remains uncut (269 bp). The ARMS-PCR size bands from 
of   IL10   -819C/T and   IL10   -1082A/G were 233 bp and 260 
bp respectively, while the internal control results in 429 
bp (  fig. 2  ,   3  ). All genotypes of the target   IL10   polymor-
phisms were in Hardy-Weinberg equilibrium (p   1   0.05). 
Frequencies for -1082A, -819C and -592C alleles in our 
study population were 48%, 47% and 50%, respectively. 
There was no evidence for strong LD between different 
SNP pairs (D’ range 0.47–0.63; r  2   range 0.20–0.35).
    The single point TDT carried out in TRANSMIT 
showed no evidence of association between promoter 
SNPs -1082A/G, -819C/T and -592C/A and development 
of PKDL p  1  0.05 ( table 1 ). The haplotype-based score test 
in TRANSMIT showed borderline significance (p = 0.05) 
for association between PKDL and the over-transmitted 
haplotype AA across the -1082A/G and -592C/A SNPs 
( table  1 ;  global     2 = 7.69; df = 3; p = 0.05). In this popula-
tion in Sudan, the GCC (33%) and ATA (30%) haplotypes 
were more frequent than other haplotypes across the 3 
promoter SNPs (  fig. 4  ). Whereas this Sudan population 
differed in allele frequency at the -1082A/G SNP com-
pared to Gambian   [21]  , Malawian   [20]   and the HapMap 
YRI population (  fig.  5  ), for the -819C/T and -592C/A 
SNPs it was the Malawian population that was at variance 
with Sudan and the other African populations.
  Discussion 
  VL is an important health problem in the Sudan, but 
remains largely a neglected disease. There is neither ef-
fective drug nor vaccines available. PKDL patients were 
suspected to be a source for VL infection in Sudan. The 
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  Fig. 1.   -592C/A genotyping using PCR-
RLFP. Lanes 1, 2, 5, 9: heterozygous; lanes 
3, 6, 8, 10: homozygous for wild type allele 
(269 bp); lane 7: homozygous for mutant 
allele (201 bp and 68 bp). Lane 4 contains 
the 50 bp DNA molecular weight marker. 
  Fig. 2.   -819C/T genotyping using ARMS-
PCR. Lane 1: 50 bp DNA molecular weight 
marker. Lanes 2, 4, 6 and 8: allele C is rep-
resented by the presence of a 233 bp PCR 
fragment. Lanes 3, 5, 6 and 9: allele T is 
represented by the presence of a 233 bp 
PCR fragment. Each two lanes represent 
one sample: lanes 2 and 3, homozygous 
(CC); lanes 4 and 5, heterozygous (CT); 
lanes 6 and 7, homozygous (TT); lanes 8 
and 9, negative controls. Lanes 2–7: a 429 
bp represents the amplified product of the 
Human Growth Factor Hormone gene (in-
ternal control). 
  Fig. 3.  -1082A/G genotyping using ARMS-
PCR. Lane 1: 50 bp DNA molecular weight 
marker. Lanes 2, 4, 6 and 8: allele A is rep-
resented by the presence of a 260 bp PCR 
fragment. Lanes 3, 5, 6 and 9: allele G is 
represented by the presence of a 260 bp 
PCR fragment. Each two lanes represent 
one sample: lanes 2 and 3, homozygous 
(AA); lanes 4 and 5, heterozygous (AG); 
lanes 6 and 7, homozygous (GG); lanes 8 
and 9, negative controls. Lanes 2–7, a 429 
bp represents the amplified product of the 
Human Growth Factor Hormone gene (in-
ternal control). 
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factors that determine development or not of PKDL are 
not well understood, but a   Leishmania- specific  cellular 
immune response seems to play a fundamental role in the 
final control of infection. This study may help to identify 
provide biomarkers for future disease surveillance and 
indicate possible avenues for immunotherapeutic inter-
vention in clinical disease.
  IL-10  and  IFN-    mRNA are observed concurrently in 
l es i o n s  fr o m  p a ti e n ts  wi th  p o s t - kal a - azar  d e rm al  l e is h -
maniasis (PKDL) that indicates the production of IL-10 
during   L. donovani   infection, and suggests a role for this 
cytokine in the regulation of immune responsiveness dur-
ing VL   [22]  . In spite of the role of IL-10 in parasite persis-
tence and its expected function in disease promotion, there 
were no single point associations between the 3 target 
polymorphisms and development of PKDL in the Masalit 
population studied here. Borderline association (global
    2 = 7.69; df = 3; nominal p = 0.05) was observed between 
PKDL and haplotypes for the 2 outer markers -1082A/G 
and -592C/A. This could indicate that other functional 
SNPs in this region could be functional variants for an as-
sociation with PKDL, or that there is a complex association 
that relies on interaction between different functional 
SNPs across the region. However, in the current study this 
association is not robust to correction for multiple testing 
and a larger sample size would be needed to confirm such 
an association. In a recent study of cutaneous leishmani-
asis in Brazil, Salhi    et  al.    found that production of IL-10 
w a s  s t r o n g l y  a s s o c i a t e d  wi th  d e v e l o p m e n t  o f  ul c e r a t e d  
skin lesions in  L. braziliensis  infection  [8] . Along with sev-
eral SNPs within the   IL10   gene, they found single point 
associations with promoter SNPs -819C/T and -592C/ A 
that were robust to correction for multiple testing, but not 
with promoter SNP -1082A/G. Functional studies demon-
strated that the -819C/T SNP in the   IL10   promoter plays a 
functional role in determining binding of nuclear tran-
scription factors and levels of  IL10  gene expression. In oth-
er studies the -1082G allele has been shown to be associ-
Table 1. Results of association analyses
Haplotype groups IL10 polymorphisms
-1082A/G -819C/T -592C/A
3 markers 2 = 11.18; df = 7; p = 0.13
2 markers 2 = 0.85; df = 3; p = 0.84
2 markers 2 = 3.09; df = 3; p = 0.38
2 markers 2 = 7.69; df = 3; p = 0.05 2 = 7.69; df = 3; p = 0.05
1 marker 2 = 0.23; df = 1; p = 0.63 2 = 0.24; df = 1; p = 0.62 2 = 28; df = 1; p = 0.60
Grey shading indicates the combinations of markers used in the haplotypes tested.
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  Fig. 4.   Haplotype frequencies (-1082A/G, -819C/T and -592C/A) 
for the   IL10   gene polymorphisms in Sudan.     
  Fig. 5.   Allele frequencies for the -1082G, -819T and -592A alleles 
in different African populations including the HapMap YRI pop-
u l a t i o n .       Farouk   /Salih   /Musa   /Blackwell   /Miller   /
Khalil    /ElHassan   /Ibrahim   /Mohamed   
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ated with higher IL-10 levels than the -1082A allele  [11] , but 
this could relate to LD across the region with other func-
tional SNPs. In the Masalit tribe LD was not strong across 
the 3 SNPs, in contrast to data from Spanish, Caucasian 
and Asians where high LD was detected. Complete LD be-
tween -592C/A and -819C/T have been observed in Asians 
  [23, 24] . Interestingly our study population showed higher 
frequency of the -1082G allele than other African groups. 
In our study there was no measurement for cytokines to 
compare different genotypes with IL-10 level.
  The 2 most frequent haplotypes in the Masalit popula-
tion were GCC and ATA (  fig. 4  ). Although not statisti-
cally significant, the ATA haplotype was over-transmit-
ted to PKDL patients in our study population. In previous 
studies, the ATA haplotype was found to be associated 
with high plasma levels of IL-10 in Finish population  [25, 
26].   In another study a slight increase in   IL10   transcrip-
tional activity of the GCC haplotypes was observed   [27] . 
The presence of other haplotypes, even in lower frequen-
cy, may be effective to differentiate between populations. 
We found the GTA haplotype to be 10% in Masalit which 
was previously described in Caucasian and Brazilian 
with 1% frequency   [28] . The haplotype GTC, ATC and 
ACA were found in Masalit with frequencies 4.3%, 8% 
and 6% respectively, while the same haplotypes were re-
spectively 1%, 4% and 1% in Caucasian and were absent 
in Brazilians. In contrast the ACC frequency, however, 
was 5% in Masalit and higher in Caucasian 29%   [28]   and 
Japanese 28%  [29]  . In this study the presence of rare hap-
lotypes, in our population may indicate genetic heteroge-
neity of functional importance.
    In conclusion there is no single point evidence for an 
association between 3 SNPs in the   IL10   gene promoter 
and susceptibility to PKDL in the Masalit ethnic group 
in Sudan, although some evidence for haplotype associa-
tion was observed. High frequencies of the previously 
identified high IL10 producing haplotypes GCC and ATA 
were present in the Masalit. Further work using larger 
samples size and a wider range of SNPs may help to elu-
cidate the role of IL-10 in PKDL development.
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Erratum
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